Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
10 April 2024 - 10:00PM
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume
measurement technology today announces the purchase of Daxor’s
BVA-100™ at a 450-bed teaching hospital in the greater Chicago
area.
“Hospitals are utilizing our BVA diagnostic to
save money by reducing length of stay while improving Hospital
Readmissions Reduction Program (HRRP) quality metrics such as
30-day readmissions and mortality,” noted Jonathan Feldschuh,
Daxor’s Chief Scientific Officer.
“The upward momentum in our sales continues with
this latest commercial win. We are committed to commercialization,
expanding our presence through new analyzer purchases, and
enhancing utilization among our existing customer base, backed by
our ezBVA LabSM service,” said Michael Feldschuh, Daxor’s CEO and
President. “We are on track to secure contracts with two additional
hospitals in the Chicago area, maintaining our positive sales
growth and successful start to the year.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Historical Stock Chart
From May 2024 to Jun 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Jun 2023 to Jun 2024